Latterell Venture Partners is a venture capital firm specializing in startups and early stage healthcare companies.
Business Model:
Revenue: $7.4M
Employees: 2-10
Address: 1 Embarcadero Ctr
City: San Francisco
State: CA
Zip: 94111
Country: US
Latterell Venture Partners is a venture capital firm specialized in startups and early stage healthcare companies, including biotechnology, pharmaceutical, research instrument, biomaterial, medical device, healthcare IT, and diagnostic ventures. The firm invests in early stage healthcare companies with innovative technologies, large market opportunities, and passionate entrepreneurs. It offers a collection of venture capital, entrepreneurial, technical, clinical, and collaborative skills enabling entrepreneurs to create successful startups. Founded in 2001, Latterell Venture Partners is based in San Francisco, California.
Contact Phone:
+14153999880
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2009 | ProteinSimple | Series C | 10M |
5/2011 | Naurex | Series A | 18M |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
9/2008 | ForteBio | Series C | 25M |
10/2005 | ForteBio | Series B | 17.3M |
11/2020 | Viracta Therapeutics | Series E | 0 |
4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
9/2005 | OncoMed Pharmaceuticals | Series A | 13.9M |
3/2010 | Pulmonx | Series C | 0 |
1/2012 | Pulmonx | Private Equity Round | 0 |
3/2009 | Neuraltus Pharmaceuticals | Series A | 17M |
6/2004 | Aria Biosystems | Series A | 5.5M |
4/2012 | Neuraltus Pharmaceuticals | Venture Round | 0 |
10/2010 | Femta Pharmaceuticals | Series A | 22M |
7/2009 | Femta Pharmaceuticals | Venture Round | 1M |
6/2007 | Evoke Pharma | Series A | 3.3M |
1/2007 | Ovalis | Series B | 0 |
9/2004 | Cellective Therapeutics | Series A | 27.5M |
5/2019 | Pulmonx | Series G | 0 |
5/2009 | Revascular Therapeutics | Series B | 3M |
7/2007 | CardioMind | Series C | 11M |
3/2008 | CardioMind | Venture Round | 22M |
6/2009 | Transcend Medical | Series B | 35M |
10/2010 | ProteinSimple | Series F | 20M |
3/2009 | Pathway Medical Technologies | Series D | 42.5M |
6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
5/2016 | Aptinyx | Series A | 0 |
7/2003 | CardioMind | Series A | 4.5M |
11/2011 | Inova Labs | Series B | 0 |
4/2017 | Viracta Therapeutics | Series B | 0 |
1/2012 | Neuraltus Pharmaceuticals | Series B | 9.6M |
12/2004 | CardioMind | Series B | 15.1M |
5/2016 | Neuraltus Pharmaceuticals | Venture Round | 0 |
8/2007 | Leptos Biomedical | Series C | 20M |
1/2012 | Transcend Medical | Series B | 16M |
2/2008 | Pathway Medical Technologies | Series C | 7.5M |
11/2005 | Ovalis | Series A | 0 |
3/2005 | XTENT | Series C | 25M |
5/2007 | Pulmonx | Series B | 20M |
11/2006 | Pathway Medical Technologies | Series B | 25M |
3/2012 | Viracta Therapeutics | Series B | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
12/2012 | Naurex | Series B | 0 |
6/2011 | Transcend Medical | Series B | 51M |
6/2008 | Meritage Pharma | Series A | 22.5M |
5/2007 | Talima Therapeutics | Series B | 19M |
1/2006 | ProteinSimple | Series B | 0 |
9/2008 | Proteolix | Series C | 79M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
11/2008 | OncoMed Pharmaceuticals | Series B | 154M |
12/2014 | Naurex | Series C | 0 |
5/2005 | Bayhill Therapeutics | Series B | 35.4M |
1/2004 | Bayhill Therapeutics | Series A | - |
4/2014 | Transcend Medical | Series C | 0 |
11/2020 | Viracta Therapeutics | Series E | 0 |
5/2019 | Pulmonx | Series G | 0 |
4/2017 | Viracta Therapeutics | Series B | 0 |
5/2016 | Neuraltus Pharmaceuticals | Venture Round | 0 |
5/2016 | Aptinyx | Series A | 0 |
12/2014 | Naurex | Series C | 0 |
4/2014 | Transcend Medical | Series C | 0 |
12/2012 | Naurex | Series B | 0 |
4/2012 | Neuraltus Pharmaceuticals | Venture Round | 0 |
3/2012 | Viracta Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|